An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis

被引:15
作者
Ribatti, D
Vacca, A
Cantatore, FP
Ria, R
Benagiano, V
Roncali, L
Dammacco, F
机构
[1] Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy
[2] Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy
[3] Univ Bari, Sch Med, Inst Rheumatol, I-70124 Bari, Italy
关键词
anti-angiogenesis; chorioallantoic membrane; cyclosporine; osteoarthritis; rheumatoid arthritis;
D O I
10.1007/s000110050610
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and Design. Angiogenesis plays an important role in the pathogenesis of rheumatoid arthritis (RA) and correlates with clinical score, synovial hyperplasia and infiltration of inflammatory cells. Many of the available treatments for RA have been shown to possess some degree of anti-angiogenic activity. Here, we studied the effect of cyclosporine, which exerts anti-angiogenic activity in vitro and in vivo [1] on angiogenesis induced in vivo in the chick embryo chorioallantoic membrane (CAM) by synovial RA and osteoarthritis (OA) tissues. Material and Methods. Wet synovial biopsies from 10 RA and 6 OA patients were treated with vehicle alone or with cyclosporine and implanted on the CAM at day 8 of incubation. On day 12, CAM tissues were assessed for the extent of angiogenesis and mononuclear cell infiltration. Results. Cyclosporine inhibited angiogenesis and reduced the number of mononuclear cells in the CAM extracellular matrix only in RA implants. Conclusions. These data provide further evidence for a central role of new-formed blood vessels in RA. Moreover, cyclosporine on account of both its immunosuppressive and its anti-angiogenic activity can be proposed for the treatment of RA.
引用
收藏
页码:418 / 423
页数:6
相关论文
共 43 条
[1]   DEVELOPMENT OF CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS - CLASSIFICATION OF OSTEOARTHRITIS OF THE KNEE [J].
ALTMAN, R ;
ASCH, E ;
BLOCH, D ;
BOLE, G ;
BORENSTEIN, D ;
BRANDT, K ;
CHRISTY, W ;
COOKE, TD ;
GREENWALD, R ;
HOCHBERG, M ;
HOWELL, D ;
KAPLAN, D ;
KOOPMAN, W ;
LONGLEY, S ;
MANKIN, H ;
MCSHANE, DJ ;
MEDSGER, T ;
MEENAN, R ;
MIKKELSEN, W ;
MOSKOWITZ, R ;
MURPHY, W ;
ROTHSCHILD, B ;
SEGAL, M ;
SOKOLOFF, L ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1986, 29 (08) :1039-1049
[2]  
ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
[3]   T-LYMPHOCYTES SYNTHESIZE AND EXPORT HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR AND BASIC FIBROBLAST GROWTH-FACTOR, MITOGENS FOR VASCULAR CELLS AND FIBROBLASTS - DIFFERENTIAL PRODUCTION AND RELEASE BY CD4+ AND CD8+ T-CELLS [J].
BLOTNICK, S ;
PEOPLES, GE ;
FREEMAN, MR ;
EBERLEIN, TJ ;
KLAGSBRUN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (08) :2890-2894
[4]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571
[5]   ANGIOGENESIS AND RHEUMATOID-ARTHRITIS - PATHOGENIC AND THERAPEUTIC IMPLICATIONS [J].
COLVILLENASH, PR ;
SCOTT, DL .
ANNALS OF THE RHEUMATIC DISEASES, 1992, 51 (07) :919-925
[6]  
CUSH JJ, 1991, CLIN ORTHOP RELAT R, P9
[7]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[8]   CYCLOSPORINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN IMMUNOREGULATORY DISORDERS [J].
FAULDS, D ;
GOA, KL ;
BENFIELD, P .
DRUGS, 1993, 45 (06) :953-1040
[9]   VASCULAR-PERMEABILITY FACTOR ENDOTHELIAL GROWTH-FACTOR (VPF/VEGF) - ACCUMULATION AND EXPRESSION IN HUMAN SYNOVIAL-FLUIDS AND RHEUMATOID SYNOVIAL TISSUE [J].
FAVA, RA ;
OLSEN, NJ ;
SPENCERGREEN, G ;
YEO, KT ;
YEO, TK ;
BERSE, B ;
JACKMAN, RW ;
SENGER, DR ;
DVORAK, HF ;
BROWN, LF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :341-346
[10]  
Folkman J, 1992, INFLAMMATION BASIC P, P821